Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7316308 | 0.94 | ITGB3 (0.55) | DGAT1ITGB3ITGA2BMCHR1ALDH1A1 | |
| SCHEMBL17551972 | 0.89 | DGAT1 (0.67) | DGAT1ITGB3ITGA2BMCHR1ALDH1A1 | |
| SCHEMBL6673906 | 0.87 | ITGB3 (0.41) | DGAT1ITGB3ITGA2BALDH1A1FFAR1 | |
| SCHEMBL3449865 | 0.83 | DGAT1 (0.56) | DGAT1ITGB3ITGA2BALDH1A1POLB | |
| SCHEMBL4623171 | 0.83 | DGAT1 (0.56) | DGAT1ITGB3ITGA2BALDH1A1POLB | |
| SCHEMBL7788810 | 0.82 | ITGB3 (0.58) | DGAT1ITGB3ITGA2BMCHR1ALDH1A1 | |
| SCHEMBL29113472 | 0.81 | MCHR1 (0.42) | DGAT1ITGB3ITGA2BMCHR1FFAR1 | |
| SCHEMBL7292707 | 0.79 | DGAT1 (0.58) | DGAT1ITGB3ITGA2BALDH1A1POLB | |
| SCHEMBL3406500 | 0.79 | DGAT1 (0.58) | DGAT1ITGB3ITGA2BALDH1A1POLB | |
| SCHEMBL7304447 | 0.79 | DGAT1 (0.58) | DGAT1ITGB3ITGA2BALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| CN-1209063-A | Vitronection receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-24 | — | — | CN | disclosed |
| CN-1209060-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-24 | — | — | CN | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | DGAT1 4449/4885ITGB3 132/4885ITGA2B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.